60 Degrees PHARMACEUTICALS, Inc. (SXTP) intrinsic value & 10-year financials
60 Degrees PHARMACEUTICALS, Inc. (SXTP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue grew 65.2% a year to $1.0M, with an average return on invested capital of -215.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.86
- Market cap
- $573.0K
- Revenue (FY2025)
- $1.0M
- Revenue growth (5-yr CAGR)
- 65.2%
- ROIC (10-yr avg)
- -215.8%
- Free cash flow (FY2025)
- -$7.0M
SXTP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.0M | -$7.4M | -$11.73 | -$7.0M | -771.6% | -334.6% |
| FY2024 | $607.6K | -$7.9M | -$18.55 | -$5.8M | -1599.0% | -358.6% |
| FY2023 | $253.6K | -$3.8M | -$0.99 | -$4.6M | -2032.8% | -178.6% |
| FY2022 | $223.2K | -$6.2M | -$2.61 | — | -784.2% | 8.4% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
60 DEGREES PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
60 DEGREES PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just -0.1% ROIC.
60 DEGREES PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, 60 DEGREES PHARMACEUTICALS, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-389.62 per share.